Brief: Solid Biosciences Reports Positive Initial Clinical Data from SGT-003

Solid Biosciences

18/02/2025 11:59

Feb 18 (Reuters) - Solid Biosciences Inc  SLDB.O :
    * SOLID BIOSCIENCES INC: SGT-003 HAS BEEN WELL-TOLERATED
WITH NO
SERIOUS ADVERSE EVENTS OBSERVED
    * SOLID BIOSCIENCES INC - AVERAGE MICRODYSTROPHIN EXPRESSION
OF
110% OBSERVED IN PHASE 1/2 TRIAL OF SGT-003
    * SOLID BIOSCIENCES - PLANS TO REQUEST FDA MEETING FOR
ACCELERATED
APPROVAL PATHWAY IN MID-2025 FOR SGT-003

Source text:  ID:nGNX47H0x5 
Further company coverage:  SLDB.O 

 ((Reuters.Briefs@thomsonreuters.com;))